Pharmacokinetic and Safety Study of HYR-PB21 vs Bupivacaine Hydrochloric Acid in Healthy Participants

Exclusion criteria

• . A history of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics;
• . Have a personal or family history of clotting disorder or hematologic abnormality, such as excessive bleeding, joint hematoma, thrombovascular disease, thrombocytopenia, or any chronic condition requiring treatment with transfusions; have a history of recurrent bleeding episodes (eg, epistaxis, bruising or gingival bleeding) within 1 month prior to Screening, or a longstanding history of such bleeding.
• . Participants who were detected to have Glucose-6-phosphate dehydrogenase(G6PD) deficiency during the screening period.
• . Females who are pregnant, lactating, or have plans to become pregnant during the study
• . History and/or recent evidence within six months prior to Screening of alcohol or drug/substance abuse disorder
• . History of clinically significant allergies, including drug allergies, or allergic bronchial asthma, or related bronchospastic conditions
• . Participants who have a history of unexplained syncope or fainting or a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration.
• . Participants who have used P-gp and/or Cytochrome P450 hepatic microsomal enzyme-inducing or inhibiting drugs (e.g., propafenone, voriconazole, fluconazole, cimetidine) within 30 days of first dosing, refer to Appendix 15-16 for detailed list